ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
2 announcements with these filters
Caplin Point's subsidiary secured USFDA approval for Foscarnet Sodium Injection. The generic drug addresses a US market with approximately ₹142.5 Crore in annual sales.
Caplin Point Laboratories' subsidiary, Caplin Steriles Limited, received final USFDA approval for its Calcium Gluconate Injection USP. The product addresses acute symptomatic hypocalcemia and targets a US market with annual sales of approximately ₹674.5 Crore ($71 million). This approval strengthens the company's injectable portfolio in the regulated US market.